Clinical studies with oncolytic adenoviruses have shown that existing viruses are safe but lack efficacy. To selectively increase the toxicity of oncolytic adenoviruses targeting colon tumours, we have inserted the yeast cytosine deaminase gene (yCD) after the fibre gene in the major late transcript. yCD was expressed using either an internal ribosome entry site (IRES) or by alternative splicing of a new exon analogous to the Ad41 long fibre exon. The IRES-CD virus gave higher yCD expression on Western blots. Both approaches result in yCD expression restricted to the period after viral DNA replication. Viral burst size was reduced by less than B10-fold by 5-fluorocytosine (5-FC), showing that expression of yCD as a late gene is compatible with virus replication. Cytopathic effect assays in colon cancer cell lines showed that both yCD viruses have B10-fold increased toxicity in the presence of the prodrug 5-FC, which is converted to 5-fluorouracil (5-FU) by yCD. Toxicity was higher following addition of 5-FC immediately after infection. The largest gain in toxicity was seen in HT29 colon cancer cells, which are the least permissive colon cancer cells for the parental virus, indicating that the new 5-FC/yCD viruses may have broader applications for colon cancer therapy than their predecessors.
Introduction
Human adenovirus 5 (Ad5) is a promising candidate virus for tumour therapy because the biology of the virus is well understood, it can be manufactured relatively easily in large amounts, and clinical trials with attenuated forms have shown that it is well tolerated except at very high doses. Three main types of modification have been proposed to convert the virus into an effective therapeutic agent. The first is deletion or regulated expression of essential viral genes, leading to tumourspecific viral replication. [1] [2] [3] [4] [5] [6] [7] [8] In principle, viruses of this type can replicate, lyse the cell, infect nearby cells and spread throughout the tumour mass until all of the tumour cells are killed. The second change is modification of the tropism of the virus. Ad5 binds to the cellular coxsackie and adenovirus receptor (CAR) through the knob domain of the fibre protein. This is followed by binding of an RGD motif in the penton base to integrins on the cell surface, which leads to endocytosis of the virus. Many groups have attempted to improve the selectivity of the virus by mutating the fibre or penton genes (reviewed by Wickham 9 ). The third type of modification that is being pursued aims to increase the toxicity of the virus. This is important because, despite its impressive cytopathic effect in tissue culture, Ad5 is barely able to cure many human tumour cell lines xenografted into nude mice. It is possible to express an unconditional toxin like TNFa from the virus, but this raises biosafety concerns in a replicating human virus. A more prudent strategy is to express a prodrug-activating enzyme. The advantage of this approach is that the toxic effect is limited to the period of exposure to the drug. The enzymes most commonly used for this purpose are HSV thymidine kinase (tk) and Escherichia coli or Saccharomyces cerevisiae cytosine deaminase, although many other prodrugactivating enzymes are being studied. 10, 11 Yeast cytosine deaminase (yCD) converts the prodrug 5-fluorocytosine (5-FC) to 5-fluorouracil (5-FU). 5-FU is a widely used cytotoxic drug that is metabolised to fluorinated riboand deoxyribonucleotides, which have multiple effects, including inhibition of thymidylate synthase (reviewed by Grem 12 ). In devising a strategy for expression of a suicide gene, one can choose between use of an early or a late transcription unit. Early expression risks killing the virus if the drug interferes with viral DNA replication. 13, 14 Late expression is more attractive because replication can increase the number of transcription templates to many thousands of copies. Provided viral replication is restricted to tumour cells, genes expressed from late promoters should also be restricted to tumour cells, so there is no a priori reason to use a tumour-specific promoter. For late expression in Ad5, there is a choice between using the major late promoter and the E2 late promoter. The E2 genes are also expressed from the E2 early promoter, making it unlikely that a linked therapeutic gene would only be expressed with late kinetics. The major late promoter drives expression of five groups of transcripts (L1-L5) with common 5 0 exons (encoding the tripartite leader) and differing polyadenylation (polyA) sites. The major late transcripts encode mainly viral core and capsid proteins.
There are two general strategies to express a new gene in a virus: addition or replacement. Addition of a gene without concomitant deletion of a viral gene can easily raise the size of the genome above the 105% packaging limit. 15 Addition of a new gene within an existing transcription unit is possible by making a fusion protein, by splicing a new exon into an existing transcript or by reinitiation of translation from an internal ribosome entry site (IRES). The IRES approach has been tested with p53, which was added after the fibre gene in the L5 transcript, although in this virus there was also a deletion of the ADP gene. 16 Replacement of a viral gene carries the risk that the virus may be less active in vivo. The E1B 55K gene is nonessential in cells lacking p53 function, 1 but an E1B 55K-deleted virus remains attenuated relative to wild-type Ad5 in most cell lines regardless of p53 status because of a defect in late viral mRNA nuclear export. [17] [18] [19] Replacement of the E1B 55K gene with a CD-tk fusion gene under a heterologous promoter permits high level CD-tk expression, and combination virus, prodrug and radiation therapy has given promising results in preclinical studies and a phase I clinical study in prostate cancer. 13, 14, 20 The E3 genes are nonessential and can be replaced with therapeutic genes, [21] [22] [23] [24] although retention of the E3 region has been shown to increase the efficacy of oncolytic adenoviruses in mouse xenograft models. 25, 26 Despite E3 being labelled as an early transcription unit, two groups of E3 transcripts, ADP and E3B, are predominantly expressed from the major late promoter with late kinetics. Since ADP is important for cell lysis, it is not an ideal candidate for replacement in an oncolytic virus, although delayed lysis can permit more prolonged transgene expression. 22 The E3B region is deleted in many laboratory strains of Ad5, including the dl1520 E1B-deleted virus used by the Onyx group in clinical trials. E3B is thus an interesting site for expression of a therapeutic gene, although deletion of the E3B 14.7 kD gene increases the neutrophil response and could hasten clearance of the virus in vivo. 27 We developed oncolytic adenoviruses targeting cells with activation of the Wnt signalling pathway by inserting binding sites for Tcf/LEF family transcription factors in the early promoters. Activation of the Wnt pathway has been found in a wide range of different tumour types, but is particularly common in colon cancer. To improve the efficacy of these viruses, we have inserted the yCD gene immediately after the fibre gene in the major late transcript. In this study, we compare two strategies to express the transgene, reinitiation of translation from an IRES and alternative splicing.
Results

Virus constructs
yCD was used because it has a lower K m and higher V max than the bacterial enzyme. 28, 29 The yCD coding sequence was inserted at the end of the L5 transcript in 'A4', a replicating adenovirus with Tcf sites in the E1A and E4 promoters. 7 Two viruses were produced ('AIC4' and 'ASC4', Figure 1 ). The AIC4 virus uses the encephalomyocarditis virus (EMCV) IRES to convert the L5 transcript into a bicistronic mRNA. The ASC4 virus uses the splice acceptor sequence from the Ad41 long fibre gene to splice the yCD cassette onto the tripartite leader exons of the major late transcript. A polyA signal was placed between the fibre and yCD genes in the ASC4 virus, with the intention of splitting the existing L5 transcript into new L5 and L6 transcripts encoding fibre and yCD, respectively. The yCD insertion contributes 520 bp to ASC4 and 1071 bp to AIC4, yielding total genome sizes that are only slightly larger than normal ( Figure 1 ). Both viruses grow as well as wild-type Ad5 on SW480 cells, which have high Tcf activity and were used as producer cells. The viruses have a particle/ plaque forming units (PFU) ratio approximately five-fold higher than the parental virus, an increase that could be explained by the increase in genome size or a slight delay in fibre expression.
yCD is expressed with late kinetics SW480 is a colon cancer cell line in which the A4 virus replicates slightly better than wild-type Ad5; Hct116 and HT29 are colon cancer cell lines with lower Tcf activity that are less permissive for A4 replication. 7, 30 To check yCD expression from the new viruses, cell extracts were collected at various times after infection and Western blots were probed for yCD and viral proteins. Despite the changes to the L5 transcript, fibre was expressed to similar levels by all three viruses, except for a slight delay and reduced level in SW480 with AIC4 ( Figure 2 ). yCD expression was detectable in all three cell lines, with stronger expression from AIC4 than ASC4 (Figure 2 ). To determine whether yCD is expressed as a late gene, cells were treated with cytosine arabinoside (ara-C) to inhibit viral replication. This had no effect on expression of early genes (E1A and DBP), but blocked expression of yCD and fibre, showing that these behave as late genes.
E2 and E4 expression in normal cells
Normal human small airway epithelial cells (SAECs) and lung fibroblasts (HLFs) were infected with the yCD viruses to test whether the A4 backbone retains its (Figure 3a ). This could be caused by contamination of the prep with wildtype virus, but this was excluded by rigorous checking of the virus preps using PCR primers specific for the wildtype E1A promoter. DBP expression was not blocked by ara-C, showing that DBP was expressed from an early promoter. This could be explained by transactivation of an early promoter by an enhancer embedded in the yCD sequence or by a change in splicing of E2 transcripts initiated at an upstream promoter. To define the start site of the offending transcripts, rapid amplification of cDNA ends (RACE) was performed using RNA from SAECs harvested 48 h after infection. The major RACE RT-PCR product had the same size in cells infected with wildtype Ad5 as with the yCD viruses (data not shown). Sequencing of cloned RACE cDNAs showed that DBP was mainly expressed from the canonical E2 early promoter, ruling out abnormal splicing or transcription initiation at a cryptic promoter within the yCD sequence. The E2 early promoter is regulated by E1A and E4orf6/7. Transactivation by E1A seems unlikely because E1A expression was not deregulated in normal cells infected with the yCD viruses, except for a small increase at late time points when the template copy number had probably increased (Figure 3a, b ). An alternative possibility is that E4orf6/7 expression is deregulated in the yCD viruses. This could be explained by transactivation of the E4 promoter by a fortuitous enhancer in the yCD gene, particularly given the proximity of the two sequences in the viral constructs. Western blotting for To test the ability of the viruses to respond to activation of the Wnt signalling pathway, LS174T colon tumour cells with a dominant-negative Tcf4 (DN-Tcf4) gene expressed from a tetracycline-regulated promoter (LS174 L8) 31 were infected with the Tcf-regulated viruses (Figure 3c ). DN-Tcf4 abolished E1A expression, as expected given the presence of Tcf sites in the E1A promoter, but only partially inhibited DBP expression from the yCD viruses showing that additional factors regulate DBP expression from these viruses (Figure 3c , lanes plus doxycycline). One of these factors is probably E4orf6/7, because E4 genes were expressed constitutively and failed to respond to DN-Tcf4 inhibition (Figure 3c ).
Fibre expression was detectable at 48 h in SAECs infected with the yCD viruses ( Figure 3a) . Despite higher fibre expression with ASC4, yCD was only detectable in SAECs infected with the AIC4 virus (Figure 3a) , presumably because the IRES is more efficient than the Ad41 splice. yCD was not detectable by Western blotting in HLFs at any time point, although this does not rule out weak expression below the detection limit of the antibody ( Figure 3b ). In summary, Western blotting shows that the yCD viruses have lost some of their specificity for cells with Tcf activation, most likely because of transactivation of the E4 promoter by a fortuitous enhancer in the yCD sequence.
The exogenous splice acceptor is used correctly in the ASC4 virus
To determine whether the yCD cassette functions correctly as an L6 transcript in the ASC4 virus, the structure of the yCD mRNA was examined by Northern blotting and RT-PCR. RNA was extracted from infected HT29 cells and Northern blots were hybridized to fibre and yCD probes (Figure 4a ). AIC4-infected cells gave a 3.0 kb band with both probes that had the size expected for the fibre-IRES-yCD mRNA. The ASC4-infected cells gave a 2.5 kb band with both probes that was bigger than the expected wild-type fibre or yCD mRNAs (2.0 and 0.7 kb, respectively). To ascertain the nature of this RNA, an RT-PCR was performed with primers in the tripartite leader and yCD. This confirmed the presence of the major 2.5 kb transcript observed on the Northern blot ( Figure 4b , ASC4 lane). The RT-PCR also showed 0.7 kb bands potentially corresponding to correctly spliced L6 RNA. The 2.5 and 0.7 kb PCR products from the ASC4-infected cells were cloned and sequenced.
A schematic description of the observed transcripts is shown in Figure 4c . The 2.5 kb band corresponds to yCD transcripts that contain the fibre gene preceded by the tripartite leader either alone (labelled t1 in Figure 4c ) or combined with the x and y leaders (t2, t3). The presence of these transcripts is explained by failure of the prototypic L5 transcripts to use the polyA signal placed between the fibre and yCD genes. The lower bands correspond to mRNAs that use the exogenous Ad41 splice acceptor to create the desired new L6 transcript. The tripartite leader was correctly used, either alone (t4) or in conjunction with the y leader (t5). Two lessabundant transcripts were observed (t6 and t7), which nevertheless still used the Ad41 acceptor. We conclude that the Ad41 splice acceptor is functioning correctly but weakly, and that the polyA signal between fibre and yCD is used inefficiently if at all. The smaller amount of correctly spliced yCD transcripts readily explains the lower yCD expression seen on Western blots with the ASC4 than the AIC4 virus ( Figure 2 ).
Viral burst size in the presence of 5-FC
To test whether 5-FC interferes with virus replication, we performed burst assays on colon cancer cell lines ( Figure  5a ). The cell pellet and culture supernatant were tested separately to detect any effect on virus release. Viral burst size was higher in SW480 than Hct116 or HT29 cells with all three viruses, as expected. In the absence of 5-FC, the yCD viruses replicated at least as well as A4, despite their higher particle to PFU ratio. Less virus was detected in the pellet fraction in Hct116 and HT29 cells after 5-FC treatment. The amount of virus in the supernatant was little changed by 5-FC treatment, indicating that the drug had little effect on virus release. We conclude that treatment with 5-FC has a small effect on the burst size of the AIC4 and ASC4 viruses.
To test whether the increased E2 and E4 expression from the yCD viruses in normal cells decreases the selectivity of the viruses at the level of viral replication, burst assays were performed in normal cells. In SAECs, the A4 virus was more than 1000-fold attenuated relative to wild-type Ad5 (Figure 5b ). The yCD viruses replicated 10-100-fold better than A4 in these cells. 5-FC had a small effect on replication comparable to that in colon cancer cell lines, consistent with the yCD expression seen by Western blotting in SAECs (Figure 3a) . In HLFs, the A4 virus was B1000-fold attenuated compared to wildtype Ad5 (Figure 5c ). The yCD viruses were again less selective than A4, but still showed B100-fold attenuation relative to wild-type Ad5. We conclude that the yCD viruses replicate better than the A4 virus in nonpermissive cell lines, but remain attenuated compared to wild-type Ad5.
5-FC increases the toxicity of the yCD viruses
Before testing the toxicity of the yCD viruses, we first looked at the sensitivity of different cell lines to 5-FU (Figure 6a ). Cells were grown in the presence of various 5-FU concentrations for 4 days and stained with crystal violet, to mimic the readout of a cytopathic effect (CPE) assay. SW480 cells were at least 10-fold more resistant show a greatly reduced apoptotic response to 5-FU, but were only slightly more resistant than the parental cells in this assay. 32 The cell lines were then infected with 10-fold dilutions of virus in the presence or absence of 800 mM 5-FC (Figure 6b -d, and 'E' in 6e). In every cell line tested, 5-FC had no effect on the toxicity of the parental A4 virus but increased the toxicity of the yCD viruses 5-10-fold (compare lanes þ and À). The gain in toxicity was comparable with AIC4 and ASC4, despite evidence from Western blotting that AIC4 gives higher yCD expression (Figure 2 ). This could indicate that low levels of enzyme are sufficient for production of toxic amounts of 5-FU, or it may simply reflect the longer duration of the CPE assay. Deletion of p53 in Hct116 did not confer resistance to 5-FC. The biggest effect was seen in HT29, the colon cancer cell line least sensitive to the parental virus, probably because they express the most yCD.
Inspection of the cultures revealed that 5-FC increased the toxicity of the yCD viruses as soon as 2 days after infection. To test whether it was better to give the drug after completion of the first cycles of viral replication, we compared addition of 5-FC either directly after infection (Figure 6f) .
Finally, the toxicity of the viruses was tested in normal cells (HLFs, Figure 6g ). All three Tcf viruses were B1000-fold less toxic than wild-type adenovirus type 5. AIC4 and ASC4 started to show some CPE at an m.o.i. of 10. This correlates with the expression of DBP and fibre seen in Figure 3 . 5-FC had a marginal effect with AIC4, presumably due to yCD expression below the detection limit of Western blotting.
In conclusion, 5-FC increased the toxicity of the yCD viruses in all colon cancer cell lines tested, but had only a minor effect in normal fibroblasts. Despite the difference in the efficiency of yCD expression from the AIC4 and ASC4 viruses, there were only small differences in the toxicity of the two viruses. The biggest gain in therapeutic response was seen in HT29 cells, which show the least response to the parental virus alone.
Discussion
We have shown that 5-FC treatment of colon cancer cells infected with an oncolytic virus expressing yCD from the major late promoter increases the cytopathic effect of the virus by about 10-fold. The magnitude of the improvement appears small because Tcf viruses are already highly active in these cells. In SW480, for example, the parental virus can kill the cells at an m.o.i. of 0.01. The largest gain in activity was seen in HT29, which are relatively resistant to Tcf viruses because of low Tcf activity. The gain in activity can be unequivocally attributed to the action of yCD on 5-FC, because both are required to see the effect. It is a complex phenomenon resulting from the combination of multiple competing factors. Minimally, these include the efficiency of conversion of 5-FC to 5-FU, the sensitivity The L5/E4 junction was chosen as the site for insertion of yCD because use of distal splice sites in the major late transcript is blocked early in infection. Use of a putative L6 transcript would thus guarantee the maximum restriction of expression to cells that are committed to viral replication, both at the level of promoter activation and splice site selection. This is desirable for a suicide gene whose expression is not restricted to tumour cells by use of a tumour-specific promoter. yCD expression was blocked by treatment of cells with ara-C, which prevents viral DNA replication, demonstrating that yCD is expressed with late kinetics. Of the two methods tested for expressing yCD, the IRES gave higher expression. Expression of a transgene using an IRES in this site was recently demonstrated with p53. 16 One disadvantage of the EMCV IRES is its relatively large size (588 bp). A recent study found that the eIF4G IRES, which is only 339 bp long, gave substantially higher expression than the EMCV IRES. 33 If the major concern is to avoid increasing the size of the virus while maintaining a full complement of viral genes, the most attractive ways to express a suicide gene are fusion to a viral protein or alternative splicing. Fusion to a late gene in the E3 region is an interesting possibility; fusion to a structural gene might result in loss of specificity if active enzyme could be packaged and escape from the endosome immediately after infection. At first glance, the complexity of splicing of the major late transcript makes alternative splicing a less attractive option. In fact, the enteric adenoviruses Ad40 and Ad41 prove that it is possible to insert an additional L6 splicing unit in the major late transcript. As a first step to test the feasibility of adding an L6 transcript to Ad5, we inserted the Ad41 L6 splice acceptor site between the fibre and yCD genes. Sequencing of mRNAs cloned from infected cells showed that the Ad41 splice acceptor was used correctly, but RT-PCR and Northern blotting both indicated that it was only used by a minor group of transcripts. Furthermore, the L5 transcript did not use its new polyA signal but instead continued to the putative L6 polyA signal. These observations demonstrate the feasibility of adding an L6 transcript to Ad5 after transfer of only a minimal stretch of Ad41 sequence. Further development could include transfer of a larger piece of the Ad41 DNA separating the long and short fibre genes to improve the efficiency of splicing and termination, or inclusion of binding sites for virus-dependent splicing enhancer factors such as the 3VDE sequence to reinforce the restriction of expression to the late phase of infection. 34 Despite the low level of correct splicing, Western blotting showed that yCD was indeed expressed from the ASC4 virus. The simplest interpretation is that it was translated from the correctly spliced 'L6' transcripts, although we cannot exclude translation from the more abundant 'L5' transcripts by reinitiation. The response to 5-FC of the AIC4 and ASC4 viruses was almost identical in the colon cancer cell lines, and there was an effect on replication and CPE in normal cells despite low or undetectable yCD expression in these cells by Western blotting. This probably indicates that the level of yCD required to convert useful amounts of 5-FC to 5-FU is low and well within the range that can be achieved with the virus. Since the therapeutic gain is only seen in the presence of the drug, the fate of 5-FC in infected cells is of great interest. At the dose used, 100% conversion would be required to kill SW480 cells unless the 5-FU was yCD in colon targeting viruses C Fuerer and R Iggo concentrated in the cells or more efficiently used than when supplied in the medium. A possible explanation is that the virus and prodrug act synergistically. Disentangling this issue with selectively replicating viruses is not simple, because the virus itself invariably shows some toxicity during the late phase of infection.
The particle to PFU ratio of the yCD viruses was fivefold higher than that of the parental virus. The difference was not associated with an obvious small plaque phenotype or a reduction in CPE or burst size. It could be due to inefficient packaging of the oversized genome, but the increase in genome size was small, particularly for ASC4, and certainly within the published 105% limit. 15 An alternative explanation is that reduced fibre expression may have resulted in the production of some fibreless viruses. Deletion of the E4 region has previously been noted to have this effect. 35 The reduction in fibre expression was most obvious at early time points, after which the yCD viruses showed normal fibre expression.
One unexpected finding was that insertion of yCD increased DBP expression in normal cells. This expression was not blocked by ara-C, suggesting that it came from an early promoter. In addition to transcripts originating from the well-characterized E2 early and late promoters, the classic Ad2 transcript map shows E2 transcripts originating from the E3/L5 junction and the E4 promoter. 36 We can rule out increased expression of DBP from the latter sites, or from a novel promoter in the yCD gene itself, because transcript mapping by RACE showed that the offending transcripts began mainly at the prototypic E2 early promoter. Direct transactivation of this promoter by an enhancer in the yCD sequence is possible. Indirect transactivation by E4orf6/7 is also possible because we have shown that E4 expression is deregulated in these viruses. We cannot distinguish between these possibilities with our current data. E2 expression in normal cells leads to virus replication and yCD expression, which can be seen as a slight decrease in the confluence of 5-FC-treated HLFs infected with the highest dose of virus and a reduction in the burst size of 5-FC-treated SAECs. It is worth pointing out in this context that the Tcf virus backbone used for these experiments has the least selectivity of our family of Tcf viruses. If greater selectivity is required we have ample scope for increasing it by addition of Tcf sites to other early promoters. 7 Alternatively, it might be possible to map the putative enhancer in the yCD sequence and then destroy it by mutagenesis. Adenoviral replication has been reported to improve at 4 mM 5-FU and decline at 250 mM 5-FU. 37 The results of that study may not exactly translate to our work because of important differences in virus design, but the overall conclusion was that drugs blocking cells in the S or G2 phases of the cell cycle generally potentiate virus replication. In particular, camptothecin and cisplatin were both compatible with virus replication, despite the fact that topoisomerase I is required for in vitro viral DNA replication and DNA interstrand crosslinks should stall the viral polymerase. This is encouraging because the two chemotherapeutics commonly given with 5-FU for colon cancer are irinotecan, a topoisomerase I inhibitor related to camptothecin, and oxaliplatin, a crosslinking agent related to cisplatin. Combination therapy with virus and 5-FU or cisplatin was previously found by the Onyx group to give better results than virus alone in xenografts 38 and gave encouraging results in patients. 39, 40 The use of nontoxic prodrugs such as 5-FC would represent a considerable gain for patients. The efficacy of 5-FC treatment can be further increased by expressing enzymes that hasten the conversion of 5-FU to 5-FdUMP, such as uracil phosphoribosyl transferase or thymidine phosphorylase. 41, 42 Of particular relevance to colon cancer, it is possible to reduce the dose of irinotecan by expressing carboxyesterase, which converts irinotecan to SN38, the active metabolite. 43 Yet another option for colon cancer is to express nitroreductase, which converts CB1954 to a bifunctional alkylating agent. 44 It remains to be seen whether yCD expression from our Tcf viruses will increase their efficacy in tumour xenograft models. 5-FC treatment alone of xenografts injected with a replicating E1B-deficient adenovirus expressing a bacterial CD gene fused to HSV tk (Ad5-CD/TKrep) was unable to eradicate tumours.
14 To achieve cures with that virus, it was necessary to give two prodrugs (5-FC and ganciclovir) combined with radiotherapy. Following infection with Ad5-CD/TKrep, expression of the CD-tk fusion protein starts early but only achieves high levels following amplification of the template copy number by viral replication. Ganciclovir was considerably more effective at blocking viral replication than 5-FC, although infection was severely attenuated by 5-FC at the concentration used in our study. 13, 14 Monotherapy for cancer is rare, and most groups now expect to see viral therapy used only in combination with other treatments. Besides major differences in the way viral replication is targeted to tumours and the wide range of different prodrug/enzyme systems under development, additional layers of complexity are provided by the need to improve tumour targeting at the level of the cell surface receptor and the need to evade neutralizing antibody after intravascular injection. [45] [46] [47] [48] [49] [50] In summary, we have developed oncolytic adenoviruses that express a prodrug-activating enzyme with late kinetics. They are selective for cells with activated Wnt signalling, but less so than the parental A4 virus probably because of transactivation of viral early promoters by an enhancer in the yCD sequence. Combination treatment of colon cancer cell lines with virus and prodrug gives a 10-fold increase in toxicity in vitro over that of virus alone.
Materials and methods
Adenovirus mutagenesis
The fibre region (nucleotides 30470-33598) of Ad5 (ATCC VR5) was cut with KpnI/XbaI and cloned into pUC19 to give pCF159. A SpeI site was inserted after the polyA site of the fibre by inverse PCR with primers AGTTTCTT TATTCTTGGGCAATGT (oCF67) and AGTCGTTTGTGT TATGTTTCAAC (oCF68) to give pCF277. yCD was cloned from S.cerevisiae genomic DNA by PCR with primers TCGCTAGCCAGGCACAATCTTCG CATTTCTTTTTTTCCAGATGGTGACAGGGGGAATGGC (oCF31) and TGACTAGTTATTCACCAATATCTTCAAA (oCF32). The product was cut with NheI and SpeI (underlined) and inserted into the XbaI site of pyCDNA3 (Invitrogen, Carlsbad, USA) to give pCF232. The EMCV IRES was cloned by PCR from the pSE280-IRES plasmid (gift of O Zillian, ISREC). This plasmid contains the EMCV IRES of pCITE-1 (Novagen, Madison, USA) cut with EcoRI and BalI and cloned into the EcoRI/ SmaI sites of pSE280 (Invitrogen, Carlsbad, USA). The IRES was amplified with primers ATGCTAGCGAATT CCGCCCCTCTC (oCF69) and ATACTAGTTATGCATAT TATCATCGTGTTT (oCF70), cut with NheI and SpeI (underlined) and inserted into the SpeI site engineered immediately downstream of the fibre to give pCF274. This plasmid contains the full-length wild-type fibre followed by the EMCV IRES. The BfrBI site at the end of the IRES (bold) can be used to introduce a foreign gene, whose first codon is the ATG of the BfrBI site. The polyA site of fibre is embedded at the end of the coding sequence and was mutated by silent mutations (GAA TAA A to GAG TAG A, where the coding sequence remains Glu-Stop). To do so, the 5 0 -end of the fibre gene was amplified by PCR from pCF274 using primers GGAATTCGCTAGTTTCTCTACTCTTGGGCAATGTA (oCF77, contains the mutant polyA signal, underlined) and GGTGGTGGAGATGCTAAACTCACTTTGGTC (oKH9) and re-introduced into pCF274 using EcoRI and BstXI. The vector obtained after backcloning is pCF328. It contains the full-length wild-type fibre sequence with a mutant polyA site followed by the EMCV IRES. This viral sequence is in a pRS406 backbone. 51 yCD was cloned by PCR with primers GTGA CAGGGGGAATGGCAAG (oCF71) and TGACTAGTT TATTCACCAATATCTTCAAA (oCF76), cut with SpeI and inserted into the BfrBI/SpeI sites of pCF278, a K7-fibre but otherwise identical derivative of pCF274, to give pCF308. An extra A (bold) was added at the end of yCD (last two codons underlined) to create a polyA signal. The junction between the IRES and yCD was corrected by PCR to give pCF317. The IRES-yCD cassette of pCF317 was backcloned with AvrII and SpeI into pCF328 to obtain pCF330, the corresponding shuttle vector.
The splice acceptor sequence was synthesized in oCF31 and used with oCF76 to amplify yCD by PCR. The product was cut with NheI and SpeI and cloned into the SpeI site of pCF277 to give pCF298. The splice cassette of pCF298 was backcloned with XbaI and SpeI into pCF328 to obtain pCF317, the corresponding yeast integrating vector.
The IRES-yCD (pCF330) or splice-yCD (pCF317) sequences were introduced into the vCF11 (A4) YAC/BAC 7 by two-step gene replacement in yeast 52 to obtain vpCF12 and vpCF13, respectively. Plasmids were checked by automated fluorescent sequencing on a Licor 4200L sequencer in the fibre region using primers IF272 (Fibre sense: GCCATTAATGCAGGA GATG) and IR281 (E4 antisense: GGAGAAAGGACT GTGTACTC). Viral genomic DNA was converted into virus by transfection of PacI-digested YAC/BAC DNA into cR1 cells. The viruses were then plaque purified on SW480 cells, expanded on SW480, purified by CsCl banding, buffer exchanged using NAP25 columns into 1 M NaCl, 100 mM Tris-HCl pH 8.0, 10% glycerol and stored frozen at À701C. The identity of each batch was checked by restriction digestion. Particle counts were based on the OD 260 of virus in 0.1% SDS using the formula 1 OD 260 ¼10
12 particles/ml. PFU titres were measured on SW480. 6 The clone names for AIC4 and ASC4 are vCF125 and vCF132, respectively. 
Western blotting
Cells were infected with 10 PFU per cell in DMEM. At 2 h after infection, the medium was replaced with complete medium plus or minus 20 mg/ml of cytosine arabinoside (Sigma, St Louis, USA). Cells were harvested at various times in SDS-PAGE sample buffer. E1A, DBP, Fibre and yCD were detected with the M73 (Santa Cruz Biotechnology, Santa Cruz, USA), B6, 53 4D2 (Research Diagnostics Inc, Flanders, USA) and 2485-4906 (Biogenesis, Poole, England) antibodies, respectively. E4orf6 and E4orf6/7 were detected with the RSA3 antibody. 54 For LS174 L8 cells, dominant-negative Tcf expression was induced with 1 mg/ml of doxycycline (Sigma, St Louis, USA). Tcf4 was detected with the N-20 antibody (Santa Cruz Biotechnology, Santa Cruz, USA).
Cytopathic effect assay
Cells in six-well plates were infected with 10-fold dilutions of virus in DMEM. At 2 h after infection, the medium was replaced with complete medium containing or not 800 mM 5-FC (Sigma, St Louis, USA). At 4 days after infection, new medium was added. Late addition of 5-FC was performed at that time. After 5-8 days (see legend to Figure 6 ), the cells were fixed with 4% formaldehyde in PBS and stained with crystal violet. To test the sensitivity to 5-FC (Sigma, St Louis, USA), the drug was added at various concentrations for 4 days before staining with crystal violet.
Virus replication assay
Cells in six-well plates were infected with 1 PFU per cell in DMEM. At 2 h after infection, the medium was replaced with complete medium containing or not 800 mM 5-FC. After 48 h, the medium and the cells were collected and centrifuged at 3000 rpm in a table-top centrifuge. The supernatant was collected, while the pellet was resuspended in medium containing 10% glycerol and lysed by three cycles of freeze-thawing. Cell extracts were obtained after centrifugation of the cellular debris. Both supernatant and cell extract were tested for virus production by counting plaques formed on SW480 cells after 10 days under 0.9% Bacto agar in DMEM 10% FCS. Two independent infections were tested in triplicate for the cell extracts. One infection was tested in duplicate for the supernatant. For SAECs and HLFs, supernatant and cell extract were collected together and tested in duplicate. Northern blotting and RT-PCR HT29 cells were infected with 10 PFU per cell in DMEM. RNA was extracted with the Qiagen Rneasy midi kit following the manufacturer's instructions (Qiagen, Hilden, Germany). In total, 10 mg total RNA per lane was resolved on a 1.2% agarose/1 Â MOPS/6.3% formaldehyde gel. RNA was transferred by capillarity with 20 Â SSC on positively charged membrane (Appligene, Strasbourg, France) and UV crosslinked to the membrane in a Stratalinker (Stratagene, La Jolla, USA). Northern blots were hybridized with random-primed 32 P-labeled probes corresponding to full-length cytosine deaminase (482 bp, PCR with oCF71 and oCF76) or a 468 bp fragment of fibre (NheI to HindIII). The membranes were prehybridized in Church Buffer (0.5 M NaPO 4 , 1 mM EDTA, 7% SDS, 1% BSA) for 2 h at 651C and hybridized in the same conditions overnight. Blots were washed in 2 Â SSC, 0.1% SDS at 651C, and then in 1 Â SSC, 0.1% SDS at 651C.
RT was performed with oligo-dT [12] [13] [14] [15] [16] [17] [18] (Amersham Biosciences, Little Chalfont, UK) and Superscript II reverse transcriptase (Invitrogen, Carlsbad, USA) according to the manufacturer's instructions. yCD transcripts were amplified with Pfu turbo (Stratagene, La Jolla, USA) using primers oCF76 and AGGATCCACTCTC TTCCGCATCGCTGTC (TPLupper). Bands were purified from a TAE agarose gel, and 3 0 A-overhangs were added with Taq DNA Polymerase (Sigma, St Louis, USA). The PCR product was cloned by TOPO TA cloning into pCR2-1-TOPO following the manufacturer's instructions (Invitrogen, Carlsbad, USA) and sequenced using primers AGGGTTTTCCCAGTCACGACGTT (M13fwd) and AGCGGATAACAATTTCACACAGGA (M13rev).
RACE cloning of the DBP mRNA cap site
SAECs were infected with 10 PFU per cell in DMEM. RNA was extracted with the Qiagen Rneasy mini kit following the manufacturer's instructions (Qiagen, Hilden, Germany). Reverse transcription was performed with a DBP-specific primer (TTGTGATGAGTCTTCCT, oCF109) and Superscript II reverse transcriptase (Invitrogen, Carlsbad, USA). RNA was digested with RNase H (Invitrogen, Carlsbad, USA) after the reverse transcription. cDNA was purified on a Qiagen PCR purification column (Qiagen, Hilden, Germany) and polyadenylated with terminal deoxynucleotidyl transferase (Amersham Biosciences, Little Chalfont, UK) according to the manufacturer's instructions. The polyadenylated cDNA was then amplified by PCR using primers oCF110 (CTGCTCCTCTTCCCGACT) and T7-Oligo(dT). (GGCCAGTGAATTGTAATACGACTCACTATAGGGAG GCGGTTTTTTTTTTTTTTTTTTTTTTTTVN, where V is G, A or C, and N is any nucleotide) with Taq DNA polymerase (Sigma, St Louis, USA). The PCR product was cloned by TOPO TA cloning and sequenced with M13fwd and M13rev primers.
